Nimotuzumab Combined With Paclitaxel as Second-line Treatment for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma With EGFR Over-expression: A Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial
Latest Information Update: 30 Aug 2024
At a glance
- Drugs Nimotuzumab (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms NOTABLE-307
- Sponsors Biotech Pharmaceutical
Most Recent Events
- 28 Aug 2024 Status changed from not yet recruiting to recruiting.
- 10 Aug 2023 New trial record